Myocardial Ischemia and Ventricular Tachycardia on Continuous Electrocardiographic Monitoring and Risk of Cardiovascular Outcomes After Non-ST-Segment Elevation Acute Coronary Syndrome (from the MERLIN-TIMI 36 Trial)

被引:13
|
作者
Harkness, James R. [1 ,2 ]
Morrow, David A. [1 ,3 ,4 ]
Braunwald, Eugene [1 ,3 ,4 ]
Ren, Fang [1 ,3 ,4 ]
Lopez-Sendon, J. [5 ]
Bode, Christopher [6 ]
Budaj, Andrzej [7 ]
Scirica, Benjamin M. [1 ,3 ,4 ]
机构
[1] TIMI Study Grp, Boston, MA USA
[2] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
[3] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Boston, MA USA
[5] Hosp Univ La Paz, Madrid, Spain
[6] Med Univ Klin, Freiburg, Germany
[7] Grochowski Hosp, Postgrad Med Sch, Warsaw, Poland
关键词
SYNDROME-THROMBOLYSIS; METABOLIC EFFICIENCY; LESS ISCHEMIA; INFARCTION; RANOLAZINE; DEFIBRILLATOR; PREVALENCE; EVENTS; MARKER;
D O I
10.1016/j.amjcard.2011.06.058
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Among patients with non-ST-segment elevation acute coronary syndromes, recurrent ischemia and ventricular arrhythmias detected on continuous electrocardiographic monitoring remain common events that are associated with worse outcomes. The relative clinical significance of both events together is not well described. We determined the risk associated with ischemia (>= 1 mm ST depression lasting >= 1 minutes) and ventricular tachycardia (VT) (>= 4 beats) detected on 7-day continuous electrocardiographic monitoring in 6,355 patients with non-ST-segment elevation acute coronary syndromes from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation Acute Coronary Syndrome Thrombolysis In Myocardial Infarction (MERLIN-TIMI) 36 trial. The patients were categorized into 4 groups according to the presence or absence of VT and ischemia. Cardiovascular death, sudden cardiac death (SCD), myocardial infarction, and recurrent ischemia were assessed during a median follow-up of 348 days. A total of 60.0% patients had no VT or ischemia, 20.0% had VT alone, 14.7% had ischemia alone, and 5.3% had both. The patients with either VT or ischemia were at increased risk of cardiovascular outcomes. The combination of ischemia and VT identified a particularly high-risk population for cardiovascular death (10.1% vs 3.0%, p <0.001), SCD (7.8% vs 0.9%, p <0.001), and myocardial infarction (15.4% vs 6.2%, p <0.001) compared to patients with neither. The addition of arrhythmia and ischemia significantly improved the clinical model for predicting cardiovascular death or SCD (p <0.001). In patients with both ischemia and VT, 66.6% of SCD occurred within 90 days of the non-ST-segment elevation acute coronary syndromes. In conclusion, in >6,300 patients with non-ST-segment elevation acute coronary syndromes, the presence of myocardial ischemia or VT alone, and particularly in combination, was independently associated with poor cardiovascular outcomes and thus provides incremental improvement in early risk stratification. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;108:1373-1381)
引用
收藏
页码:1373 / 1381
页数:9
相关论文
共 20 条
  • [1] Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 Trial
    Scirica, Benjamin M.
    Sabatine, Marc S.
    Jarolim, Petr
    Murphy, Sabina A.
    de Lemos, James L.
    Braunwald, Eugene
    Morrow, David A.
    EUROPEAN HEART JOURNAL, 2011, 32 (06) : 697 - 705
  • [2] Continuous ST-Segment Monitoring in Contemporary Acute Coronary Syndrome Patients The Magic of MERLIN-TIMI 36
    Tzivoni, Dan
    Krucoff, Mitchell W.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (16) : 1422 - 1424
  • [3] Ischemia Detected on Continuous Electrocardiography After Acute Coronary Syndrome Observations From the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) Trial
    Scirica, Benjamin M.
    Morrow, David A.
    Budaj, Andrzej
    Dalby, Anthony J.
    Mohanavelu, Satishkumar
    Aroesty, Julian
    Hedgepeth, Chester M.
    Stone, Peter H.
    Braunwald, Eugene
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (16) : 1411 - 1421
  • [4] Relationship Between Nonsustained Ventricular Tachycardia After Non-ST-Elevation Acute Coronary Syndrome and Sudden Cardiac Death Observations From the Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial
    Scirica, Benjamin M.
    Braunwald, Eugene
    Belardinelli, Luiz
    Hedgepeth, Chester M.
    Spinar, Jindrich
    Wang, Whedy
    Qin, Jie
    Karwatowska-Prokopczuk, Ewa
    Verheugt, Freek W. A.
    Morrow, David A.
    CIRCULATION, 2010, 122 (05) : 455 - U36
  • [5] B-Type Natriuretic Peptide and the Effect of Ranolazine in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Observations From the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) Trial
    Morrow, David A.
    Scirica, Benjamin M.
    Sabatine, Marc S.
    de Lemos, James A.
    Murphy, Sabina A.
    Jarolim, Petr
    Theroux, Pierre
    Bode, Christophe
    Braunwald, Eugene
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (12) : 1189 - 1196
  • [6] Economic Impact of Angina After an Acute Coronary Syndrome Insights From the MERLIN-TIMI 36 Trial
    Arnold, Suzanne V.
    Morrow, David A.
    Lei, Yang
    Cohen, David J.
    Mahoney, Elizabeth M.
    Braunwald, Eugene
    Chan, Paul S.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2009, 2 (04): : 344 - U130
  • [7] Efficacy of Ranolazine in Patients With Chronic Angina Observations From the Randomized, Double-Blind, Placebo-Controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial
    Wilson, Sean R.
    Scirica, Benjamin M.
    Braunwald, Eugene
    Murphy, Sabina A.
    Karwatowska-Prokopczuk, Ewa
    Buros, Jacqueline L.
    Chaitman, Bernard R.
    Morrow, David A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (17) : 1510 - 1516
  • [8] Effect of ranolazine on at a fibrilla on in patients with non-ST eleva on acute coronary syndromes: observations from the MERLIN-TIMI 36 trial
    Scirica, Benjamin M.
    Belardinelli, Luiz
    Chaitman, Bernard R.
    Waks, Jonathan W.
    Volo, Samuel
    Karwatowska-Prokopczuk, Ewa
    Murphy, Sabina A.
    Cheng, Mei L.
    Braunwald, Eugene
    Morrow, David A.
    EUROPACE, 2015, 17 (01): : 32 - 37
  • [9] Angiographic Outcomes With Early Eptifibatide Therapy in Non-ST-Segment Elevation Acute Coronary Syndrome (from the EARLY ACS Trial)
    Kunadian, Vijay
    Giugliano, Robert P.
    Newby, L. Kristin
    Zorkun, Cafer
    Guo, Jianping
    Bagai, Akshay
    Montalescot, Gilles
    Braunwald, Eugene
    Califf, Robert M.
    Van de Werf, Frans
    Armstrong, Paul W.
    Harrington, Robert
    Gibson, C. Michael
    AMERICAN JOURNAL OF CARDIOLOGY, 2014, 113 (08) : 1297 - 1305
  • [10] High-sensitivity C-reactive protein predicts adverse outcomes after non-ST-segment elevation acute coronary syndrome regardless of GRACE risk score, but not after ST-segment elevation myocardial infarction
    Raposeiras Roubin, Sergio
    Barreiro Pardal, Cristina
    Roubin-Camina, Filomena
    Ocaranza Sanchez, Raymundo
    Alvarez Castro, Ezequiel
    Paradela Dobarro, Beatriz
    Maria Garcia-Acuna, Jose
    Aguiar Souto, Pablo
    Jacquet Hervet, Michel
    Jose Castroman, Maria
    Arufe, Isabel
    Outes, Belen
    Victoria Reino-Maceiras, Maria
    Abu Assi, Emad
    Ramon Gonzalez-Juanatey, Jose
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2013, 32 (02) : 117 - 122